ClinicalTrials.gg
RecruitingNCT01037387Updated Mar 6, 2023

Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients

A Phase 4 interventional study of Control and NIMV group in Chronic Obstructive Pulmonary Disease and Hypercapnic, sponsored by Hospital Universitario La Paz. Recruiting at 1 site in Spain. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-06.

Sponsored by Hospital Universitario La Paz · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.

Planned enrollment
202nd of 238
50 · median 336
Started
2025
with 18 others
Phase 4
40 of 309
5 open now
Primary completion
2025-12
later than 12 of 44 live
Registered
58th of 309
by date

Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 202nd largest by planned enrollment of the 238 interventional ones that give a count, is one of 19 that started in 2025, is one of 40 in phase 4, reaches primary completion later than 12 of the 44 other live ones, and was the 58th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, or all of them as a file.
02

Study summary

Parallel, randomized and controlled clinical trial to evaluate the effect of 12 months of noninvasive mechanical ventilation versus conventional treatment in hypercapnic patients with stable COPD.

Main objective: To evaluate the effect of 12 months of noninvasive ventilation on c-reactive protein concentration and daily physical activity in hypercapnic patients with stable COPD.

Secondary objectives: To compare the plasmatic concentration of other inflammatory biomarkers between COPD patients with conventional treatment and wich noninvasive ventilation. To determine the response of breathlessness, health-related quality of life and lung function to noninvasive ventilation. To identify the COPD patients with a higher gasometric and clinic response to noninvasive ventilation.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Hypercapnic
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 45-75 yrs.
  • diagnosis (postbronchodilator /FVC \< 0.7) for at least 6 months.
  • FEV1 \< 45% predicted
  • Baseline pH 7.35-7.45
  • Baseline PaCO2>45 mmHg breathing current air
  • Smoking history (>15 pack-year)
  • Clinically stable for at least the last three months
  • Pharmacological treatment optimized in the last two years.

Exclusion criteria

Exclusion Criteria:

  • Previous diagnosis of asthma, other airway obstructive disease, sleep apnea syndrome, interstitial lung disease, chest wall disease or neuromuscular disease.
  • Apnea-hypopnea index > 10/h
  • Morbid obesity ( > 45 Kg/m2)
  • Previous diagnosis of ischaemic heart disease, cardiac failure, cirrhosis, chronic renal failure, rheumatoid arthritis or other inflammatory disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Control

    Conventional treatment for COPD

    Drug: Control

  • Experimental
    NIMV group

    NIMV: Conventional treatment plus noninvasive mechanical ventilation

    Device: NIMV group

Interventions

  • DrugControl

    Current treatment according to the ATS/ERS guidelines

    Also known as: Bronchodilator agents and inhaled corticosteroids

  • DeviceNIMV group

    Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).

    Also known as: Bronchodilator agents and inhaled corticosteroids.

06

What researchers measure

Primary outcomes

  1. daily physical activity and plasmatic concentration of C-reactive protein

    Time frame: 12 months

Secondary outcomes

  1. Seric concentrations of homocysteine, proBNP, fibrinogen, cholesterol, tg, tnf-alpha, IL-1, IL-6 and 8-isoprostane

    Time frame: 12 months

  2. PaO2, PaCO2, pH, IC, VCIN, FVC, FEV1, FEV1/FVC, TLC, FRC/TLC, RV/TLC,PImax, PEmax, TTmus, 6MWD

    Time frame: 12 months

  3. BDI/TDI, SF-36, SGRQ, LCADL

    Time frame: 12 months

  4. Adverse effects

    Time frame: 12 months

  5. Cardiovascular effects, exacerbations, hospitalizations and mortality

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario La Paz
    Madrid, 28034, Spain
    Recruiting
    • María Antonia Gómez-Mendieta, MD · Contactfgr01m@gmail.com · 917277253
    • María Antonia Gomez-Mendieta, MD · Principal investigator
    • Claudia Llontop · Principal investigator
    • Francisco Garcia-Rio, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 0 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2009
First posted
Dec 23, 2009
StartEst.
Dec 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Mar 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01037387
Lead sponsor
Hospital Universitario La Paz
Responsible party
Francisco Garcia-Rio (MD, Hospital Universitario La Paz) — Principal investigator
First posted
Dec 23, 2009
Start date
Dec 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 6, 2023

Study contacts

María Antonia Gomez-Mendieta, MD
Contact
fgr01m@gmail.com
34917277253
Maria Antonia Gómez-Mendieta
principal investigator · Hospital Universitario La Paz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion